{"id":"W2111872404","doi":"10.1517/14656566.2012.732998","title":"Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Incyte; Massachusetts Medical Society","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical trial; Janus kinase; Anemia; Internal medicine; Oncology; Tolerability; Adverse effect; Pharmacology; Bone marrow; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003106494,0.0008889435,0.002178234,0.0004760789,0.0001077402,0.00006370641,0.0001441304,0.0003997777,0.001110511],"category_scores_gemma":[0.00001126387,0.0006406368,0.0003621666,0.0003046674,0.00008994988,0.0002081817,0.00003840748,0.0005406461,0.0001332429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003128076,"about_ca_system_score_gemma":0.000234257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008598385,"about_ca_topic_score_gemma":0.000004820738,"domain_scores_codex":[0.9968314,0.0004399289,0.0008112573,0.000861373,0.0004312123,0.0006247966],"domain_scores_gemma":[0.9984408,0.0002142247,0.0002527506,0.0004683285,0.0000535986,0.0005702834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002234152,0.001758669,0.0003817327,0.001188742,0.000269999,0.00002408407,0.0006691123,6.072214e-8,0.00004078503,0.0003375611,0.003009504,0.9920963],"study_design_scores_gemma":[0.003961284,0.001050708,0.0001583025,0.00653432,0.00007711109,0.00008853888,0.00003267297,0.000006809523,0.0005409996,0.000008776744,0.9869762,0.0005642665],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004083132,0.994915,0.000002403149,0.0004648462,0.001164421,0.00210421,0.00007891982,0.00009684968,0.0007650487],"genre_scores_gemma":[0.0002238883,0.992863,0.0005348386,0.002256328,0.00197222,0.001336025,0.0004550589,0.0001806453,0.0001780056],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9915321,"threshold_uncertainty_score":0.9998026,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1715041564346279,"score_gpt":0.4699678213059147,"score_spread":0.2984636648712869,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}